科兴制药: 简式权益变动报告书（科益医药、邓学勤）

Core Viewpoint - The report outlines the equity changes of Sinovac Biotech Ltd, indicating a reduction in shareholding by the information disclosing parties, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. and Deng Xueqin, due to a planned divestment and passive dilution from stock vesting [1][3]. Group 1: Information Disclosure Obligors - The information disclosing parties include Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. and Deng Xueqin, with the former holding 100% of the shares of the latter [4][5]. - Deng Xueqin serves as the legal representative and is the chairman of the company, with no adverse record in the securities market over the past three years [4][5]. Group 2: Equity Change Details - The total number of shares held by the disclosing parties before the equity change was 131,778,347 shares, representing 66.32% of the total share capital at that time [6][10]. - After the equity change, the total number of shares held decreased to 129,767,472 shares, accounting for 65.00% of the current total share capital [7][10]. - The reduction in shareholding was due to a combination of planned divestment and passive dilution from stock vesting, leading to a decrease of 2,010,875 shares or 1.32% [9][10]. Group 3: Future Plans - The disclosing parties plan to reduce their holdings by up to 5,989,200 shares, which is not more than 3.00% of the total share capital [9]. - There are no current plans for additional share purchases within the next 12 months, but the possibility of future changes remains open [6][13].